Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections

Statistics in Medicine

Volumn 20, Issue 24, 2001, Pages 3741-3751

  Klar, Neil ^a   Donner, Allan ^b  

^a CANCER CARE ONTARIO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANALYTICAL ERROR; ARTICLE; CALCULATION; CLINICAL RESEARCH; DATA ANALYSIS; ERROR; HAZARD; METHODOLOGY; RANDOMIZATION; RISK ASSESSMENT; SAMPLE SIZE; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE; SURVIVAL ANALYSIS;

EID: 0035977433     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1136     Document Type: Article

References (17)

1. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer
2. Mid-trial design reviews for sequential clinical trials
3. Interim analysis: The alpha spending approach
4. Evaluation of experiments with adaptive interim analyses
5. Designed extension of studies based on conditional power
6. Self-designing clinical trials
7. Statistical inference for self-designing clinical trials with a one-sided hypothesis
8. Adaptive sample size calculation in group sequential trials
9. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential approaches
10. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time
11. Repeated significance testing for a general class of statistics used in censored survival analysis
12. Sequential analysis of the proportional hazards model
13. Sequential analysis of survival times in clinical trials
14. Repeated significance tests on accumulating data
15. Design and analysis of group sequential tests based on the type I error spending rate function
16. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint
17. Modifying the design of ongoing trials without unblinding